Mycronic (MYCR) investor relations material

Executive summary

• Q3 order intake rose 10% to SEK 2,667m; net sales increased 38% to SEK 2,356m, and EBIT reached SEK 610m at a 25.9% margin.

• All divisions posted double-digit sales growth; backlog reached a record SEK 5,566m.

• Global Technologies drove sales and EBIT growth, but its unusually strong product mix and volume effects are not expected to repeat at the same level.

• Nine-month order intake grew 39% to SEK 8,113m and sales rose 23% to SEK 7,276m.

Financial highlights

• Q3 gross margin was 52.1%, versus 47.1% a year earlier; EBIT margin was 25.9%, versus 15%.

• Q3 net profit was SEK 471m and EPS SEK 2.41; nine-month net profit was SEK 1,713m and EPS SEK 8.77.

• Aftermarket revenue reached a Q3 record SEK 606m; rolling 12-month sales were SEK 9,297m, with a 28% EBIT margin and aftermarket revenue of SEK 2,186m, or 24% of sales.

• Q3 sales growth was 38% reported and 35% at constant exchange rates; nine-month growth was 23% reported and 28% at constant exchange rates.

Outlook and guidance

• FY 2026 net sales outlook raised to SEK 9.75bn from SEK 9.25bn.

• Long-term targets: SEK 20bn net sales by 2032–2035, ~25% EBIT margin, and an EBIT margin above 10% in each division.

• PCB test capacity expansion is on schedule for a 25% increase, ready at the start of 2027 with final ramp-up toward the end of Q1.

• R&D growth is likely to slow, while spending is expected to remain stable.